Galectin-3 expression in non-small cell lung carcinoma.

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Galectins, a family of beta-galactoside-binding lectins, play a role in cancer development.
• Galectin-3 has been implicated in malignant transformation and tumor progression.

Purpose of the Study:

• To investigate the immunohistochemical expression of galectin-3 in non-small cell lung carcinomas (NSCLCs).
• To determine the association between galectin-3 expression patterns and clinical outcome in NSCLC patients.
• To explore the correlation between nuclear galectin-3, TTF-1 expression, and patient prognosis.

Main Methods:

• Immunohistochemical analysis of galectin-3 expression in 81 radically resected NSCLC samples.
• Evaluation of cytoplasmic and nuclear expression patterns of galectin-3.
• Assessment of concomitant expression of nuclear galectin-3 and thyroid transcription factor-1 (TTF-1).

Main Results:

• The predominant pattern of galectin-3 expression was cytoplasmic (median 80.0%).
• Nuclear and cytoplasmic co-expression of galectin-3 was observed in a median of 3.5% of tumor cells.
• Concomitant expression of nuclear galectin-3 and TTF-1 was independently associated with a worse clinical outcome (HR 2.0; P = 0.01).

Conclusions:

• Galectin-3 is primarily expressed in the cytoplasm of NSCLC cells.
• Nuclear galectin-3 expression, particularly when co-expressed with TTF-1, is a significant indicator of poor prognosis in NSCLC.
• These findings suggest that nuclear galectin-3 and TTF-1 co-expression could serve as a predictive biomarker for NSCLC progression.